The BioVendor company participates in research and development projects funded from public sources together with the key partners in science and research in the Czech Republic.
TH04010303: Development of microRNA-based biomarkers for diagnostics of cancer chemoresistance (01/2019 – 12/2021)
FW01010285: Development and application of novel methodology for monitoring the effectiveness of hypolipidemic therapy and for the risk assessment of subsequent atherosclerotic complications (01/2020 – 12/2023)
FW01010052: Development of new laboratory tests for the diagnosis of inflammation, sepsis and cardiovascular diseases based on chemiluminescence analysis on automated platforms (1/2020 – 12/2023)
FW03010174: Differential diagnosis of cardiomypathy and cardiotoxicity in oncologic patients based on innovative molecular-diagnostic platforms (1/2021 – 12/2024)
EG16_084/0008832: APPLICATION in the field of in vitro diagnostics (1/2017 – 1/2020)
CZ.01.1.02/0.0/0.0/16_092/0008633: Research and development in the field of in vitro diagnostics 2017 - 2018
CZ.01.1.02/0.0/0.0/19_297/0019598: Automation in the field of IN VITRO DIAGNOSTICS 2020 - 2022
Automation in the field of IN VITRO diagnostics.
This project is cooperating with the European Union.
The aim of the project is to expand the company's research and development center. Which lies in the acquisition of technology for RnD in the project will lead to an increase in sales and also to increase international competitiveness and strengthen the company's position in the market.
About project in czech
AUTOMATIZACE V OBLASTI IN VITRO DIAGNOSTIKY
je spolufinancován Evropskou unií.
Cílem projektu je rozšíření výzkumně-vývojového centra společnosti, které spočívá v pořízení technologií pro VaV v oblasti imunodiagnostiky. Realizace projektu povede k nárůstu tržeb a exportu společnosti a ke zvýšení mezinárodní konkurenceschopnosti a upevnění pozice společnosti na trhu.
O projektu
CZ.01.01.01/01/22_002/0000363: Personalized genetic analyzes based on the principle of next generation sequencing technology
is co-financed by the European Union.
The main goal of the project is research and development in the field of molecular diagnostics with a focus on the development of personalized genetic tests based on the principle of the next generation sequencing (NGS) method.
CZ.01.01.01/01/22_002/0000363: Personalizované genetické analýzy na principu sekvenační technologie sekvenování nové generace
je spolufinancován Evropskou unií.
Hlavním cílem projektu je výzkum a vývoj v oblasti molekulární diagnostiky se zaměřením na vývoj personalizovaných genetických testů založených na principu metody sekvenování nové generace (NGS).
O projektu
CZ.01.01.01/01/22_002/0000377: APPLICATION in the field of modern immunodiagnostic technologies
is co-financed by the European Union.
The main goal of the project is research and development in the field of human in vitro diagnostics with a focus on automation and new technologies.
CZ.01.01.01/01/22_002/0000377: APLIKACE v oblasti moderních imunodiagnostických technologií
je spolufinancován Evropskou unií.
Hlavním cílem projektu je výzkum a vývoj v oblasti humánní in vitro diagnostiky se zaměřením na automatizaci a nové technologie.
O projektu
TJ02000049: Development and validation of innovative detection systems for quantification of urinary microRNAs in diagnosis of urologic cancers 2019 - 2021
Project TN02000109 Personalised Medicine: PERMED - From Translational Research into Biomedical Applications is co-financed with the state support of the Technology Agency of the Czech Republic as part of the National Centers of Competence Program.
Project TN02000017: NaCeBiVet - National Centre for Biotechnology in Veterinary Medicine 01/23 – 12/28
CZ.02.1.01/0.0/0.0/16_026/0008451: INBIO - Inženýrství nových biomateriálů a biofarmak pro diagnózu a léčbu cerebrovaskulárních a neurodegenerativních onemocnění.
O projektu